[Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol].
Lp(a) has recently begun to attract attention as a risk factor of atherosclerotic disease, especially of ischemic heart disease. The Lp(a) concentration in the serum was shown to be important for chronic hemodialysis patients who have high mortality due to cardiovascular disease. Nicotinic acid derivatives, which are recognized for their capacity to lower the serum Lp(a) concentration, are effective against a high Lp(a) concentration in hemodialysis patients. In this study, niceritrol which is a nicotinic acid derivative was tested on hemodialysis patients and healthy controls by investigating the serum nicotinic acid level. Serum nicotinic acid concentration was also measured by the severity of renal dysfunction of patients untreated by niceritrol. The blood nicotinic acid concentration in healthy controls (n = 4) was changed after 2 hrs by the administration of niceritrol from 9.8 +/- 1.4 ng/ml to 192.7 +/- 23.1 ng/ml then slowly decreased. Chronic hemodialysis patients who take niceritrol every day showed the highest nicotinic acid serum concentration (500-1,000 ng/ml) on the day without hemodialysis and the serum level decreased with dialysis for 4 hrs to 25-80%. There was no significant difference in the nicotinic acid level in the serum between healthy controls (n = 10), chronic glomerulonephritis patients (n = 7), chronic renal failure patients (n = 8) and chronic hemodialysis patients (n = 17). Lp(a) concentration in the serum, however, was increased with greater severity of renal dysfunction, The side effect was not observed in any cases administered niceritrol. These data suggest nicotinate derivatives are effective for hemodialysis patients. High nicotinic acid level in the serum after treatment with niceritrol was lowered by dialysis. It is plausible that the nicotinate level in patients without niceritrol treatment did not influence the Lp(a) concentration, because there was no increase in the nicotinate level of the serum even if the patients had renal dysfunction.
Saika
Y
Y
Department of Internal Medicine, Ryoushukai Fujii Hospital, Osaka, Japan.
Kodama
N
N
Kimura
K
K
Fujii
R
R
Ohtani
H
H
Mune
M
M
Mimura
K
K
Maeda
T
T
Yukawa
S
S
D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D017270:Lipoprotein(a) / Q000097:blood; D009525:Niacin / Q000097:blood*; D009531:Niceritrol / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006435:Renal Dialysis; D012307:Risk Factors
D000960:Hypolipidemic Agents; D017270:Lipoprotein(a); D009525:Niacin; D009531:Niceritrol